Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.36 |
| ▸ | CA2 | P00918 | 18/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2191452 | 0.98 | CA1 (0.35) | CA1CA2NOS3NOS1NOS2 | |
| SCHEMBL15759497 | 0.84 | DGAT1 (0.34) | CA1CA2CA12CA9ELANE | |
| SCHEMBL25515866 | 0.83 | CA1 (0.43) | CA1CA2 | |
| SCHEMBL22930932 | 0.81 | CA12 (0.35) | CA1CA2CA12CA9ELANE | |
| SCHEMBL12508285 | 0.80 | CA1 (0.32) | CA1CA2NOS3NOS1NOS2 | |
| SCHEMBL3812152 | 0.79 | NOS3 (0.39) | CA1CA2NOS3NOS1NOS2 | |
| SCHEMBL17837034 | 0.78 | NR1D1 (0.31) | CA1CA2CA12CA9 | |
| SCHEMBL17837035 | 0.78 | NR1D1 (0.31) | CA1CA2CA12CA9 | |
| SCHEMBL13897077 | 0.78 | NOS3 (0.38) | CA1CA2NOS3NOS1NOS2 | |
| Water SCHEMBL21810558 | 0.78 | NOS3 (0.38) | CA1CA2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080254198-A1 | Method of Preparing Creatine Ester Salts and Uses Thereof | BIO-ENGINEERED SUPPLEMENTS & NUTRITION, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-20250017886-A1 | FORMULATIONS AND METHODS FOR INCREASING CREATININE LEVELS IN PLASMA, EXTRACELLULAR FLUID AND/OR INTRACELLULAR COMPARTMENTS | VIREO SYSTEMS, INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-20230159442-A1 | CELLULAR ENERGY COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | VIREO SYSTEMS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20190247354-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2019-08-15 | — | — | US | disclosed |
| US-10206897-B2 | Creatine ester anti-inflammatory compounds and formulations | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180153844-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153844-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-06-07 | — | — | US | disclosed |
| US-9833427-B2 | Creatine ester anti-inflammatory compounds and formulations | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833427-B2 | Creatine ester anti-inflammatory compounds and formulations | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170202241-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2017-07-20 | — | — | US | disclosed |
| US-20120302519-A1 | MULTIPLE SUBSTITUTED FLUOROMETHANES AS SELECTIVE AND BIOACTIVE ISOSTERES | MEH ASSOCIATES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20110224174-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2011-09-15 | — | — | US | disclosed |
| US-20110224174-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2011-09-15 | — | — | US | disclosed |
| WO-2011097421-A1 | MULTIPLE SUBSTITUTED FLUOROMETHANES AS SELECTIVE AND BIOACTIVE ISOSTERES | MEH ASSOCIATES, INC (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2011-07-14 | — | — | US | disclosed |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2011-07-14 | — | — | US | disclosed |
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | REGENTS OF THE UNIVERSITY OF NEBRASKA, BOARD OF | 2009-05-28 | — | — | US | disclosed |
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | REGENTS OF THE UNIVERSITY OF NEBRASKA, BOARD OF | 2009-05-28 | — | — | US | disclosed |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2007-08-30 | — | — | US | disclosed |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | VENNERSTROM JONATHAN L | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017886-A1 | FORMULATIONS AND METHODS FOR INCREASING CREATININE LEVELS IN PLASMA, EXTRACELLULAR FLUID AND/OR INTRACELLULAR COMPARTMENTS | GLS, ALB, REN | CA1 2637/4885CA2 2553/4885NOS3 3880/4885 |
| US-20180153844-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | CA1 2415/4885CA2 901/4885NOS3 532/4885 |
| US-20190247354-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | CA1 2415/4885CA2 901/4885NOS3 532/4885 |
| US-20170202241-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | CA1 3741/4885CA2 3569/4885NOS3 3416/4885 |
| US-10206897-B2 | Creatine ester anti-inflammatory compounds and formulations | CKMT1A; CKMT1B, CPT1B, CRAT | CA1 2415/4885CA2 901/4885NOS3 532/4885 |
| US-20110172306-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | CA1 3741/4885CA2 3569/4885NOS3 3416/4885 |
| US-20120302519-A1 | MULTIPLE SUBSTITUTED FLUOROMETHANES AS SELECTIVE AND BIOACTIVE ISOSTERES | F2R, FDPS, MRGPRX2 | CA1 2187/4885CA2 1964/4885NOS3 2883/4885 |
| US-20110224174-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | CA1 2415/4885CA2 901/4885NOS3 532/4885 |
| US-20070203076-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, PYGM | CA1 3741/4885CA2 3569/4885NOS3 3416/4885 |
| US-20230159442-A1 | CELLULAR ENERGY COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | PC, PCK2, MAVS | CA1 3184/4885CA2 1160/4885NOS3 2442/4885 |
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | CA1 2415/4885CA2 901/4885NOS3 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.